Abstracts Archive - Page 343 of 2425 - ACR Meeting Abstracts

Abstract Number: 2194 • ACR Convergence 2023
Association of Self-perceived Oral Health Status with ESSPRI Reported by Sjögren’s Syndrome Patients
Oscar E. Alvarez-González¹, Hector Guerra², Elena A. Quintana-Aguilar², Sandra P. Arroyo-Sánchez², Jesus S. Cortez-Gutierrez², Jesus Alberto Cardenas-De la Garza³, Francisco J. Torres-Quintanilla⁴, Janett Riega-Torres⁵, Cassandra Michele Skinner-Taylor⁵ and Dionicio A. Galarza-Delgado⁶, ¹Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, Mexico, ²Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, ³Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico, ⁴Hospital Universitario "Dr. José Eleuterio González", UANL, Monterrey, Mexico, ⁵Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, ⁶Hospital Universitario UANL, Monterrey, Mexico
Background/Purpose: Salivary gland hypofunction, manifested as xerostomia in Sjögren's syndrome (SS), causes dental, language, and nutritional problems, leading to a detriment in oral health. The…
Abstract Number: 2167 • ACR Convergence 2023
24-week, Post-Marketing Surveillance Analysis of Upadacitinib in Japanese Patients with Rheumatoid Arthritis (Encore1)
Tatsuya Atsumi¹, Nami Okamoto², Nobunori Takahashi³, Naoto Tamura⁴, Atsuo Nakajima⁵, Ayako Nakajima⁶, Takao Fujii⁷, Hiroaki Matsuno⁸, Takeshi Kawaberi⁹, Naomi Sunaga⁹, Yuki Tsujita¹⁰, Sumi Chonan⁹, Masataka Kuwana¹¹ and Michiaki Takagi¹², ¹Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Sapporo, Japan, ²Department of Paediatrics, Osaka Rosai Hospital, Sakai-city, Japan, ³Department of Orthopedic Surgery, Aichi Medical University, Nagakute, Japan, ⁴Department of Internal Medicine and Rheumatology, Juntendo University Faculty of Medicine, Tokyo, Japan, ⁵Ueno Dialysis Clinic, Taito-ku, Japan, ⁶Center for Rheumatic Diseases, Mie University Hospital, Tsu, Japan, ⁷Department of Rheumatology and Clinical Immunology, Wakayama Medical University, Wakayama, Japan, ⁸Matsuno Clinic for Rheumatic Diseases, Toyama City, Japan, ⁹AbbVie GK, Minato-ku, Japan, ¹⁰Abbvie GK, Minato City Tokyo, Japan, ¹¹Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ¹²Department of Orthopaedic Surgery, Yamagata University Faculty of Medicine, Yamagata, Japan
Background/Purpose: Upadacitinib (UPA) was approved in 2020 in Japan for the treatment of "Rheumatoid arthritis (RA) patients with inadequate response to conventional therapy, including inhibition…
Abstract Number: 2166 • ACR Convergence 2023
Long-Term Effects of Abatacept on Arthritis and Atherosclerosis in Older vs Younger Patients with Rheumatoid Arthritis: 3-year Results of a Prospective, Multicenter, Observational Study
Zento Yamada¹, Sei Muraoka¹, Mai Kawazoe², Wataru Hirose³, Hajime Kono⁴, Shinsuke Yasuda⁵, Takahiko Sugihara⁶ and Toshihiro Nanki², ¹Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Ota-ku, Japan, ³Hirose Clinic of Rheumatology, Saitama, Japan, ⁴Teikyo University School of Medicine, Tokyo, Japan, ⁵Department of Rheumatology, Graduate School of Medical and Dental Science, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, ⁶Toho University, Tokyo, Japan
Background/Purpose: Patients with rheumatoid arthritis (RA) are at an increased risk of cardiovascular disease secondary to atherosclerosis. Although it has been reported that TNF inhibitor…
Abstract Number: 2184 • ACR Convergence 2023
Development of Salivary Gland Organoids to Study Sjögren Syndrome
Loïc Meudec¹, Negaar Goudarzi², Juliette Pascaud³, Fanny Jaulin², Xavier Mariette⁴ and Gaetane Nocturne⁵, ¹CHU Kremlin-Bicêtre, Rheumatology, Le Kremlin-Bicêtre, France, ²INSERM UMR 981, Institut Gustave Roussy, Villejuif, France, Villejuif, France, ³Center for Immunology of Viral Infections and Autoimmune Diseases, INSERM UMR 1184, FHU CARE, Université Paris-Saclay, Le Kremlin-Bicêtre, France, ⁴Université Paris-Saclay, Le Kremlin-Bicêtre, France, ⁵APHP, Le Kremlin-Bicêtre, France
Background/Purpose: Sjögren disease (Sjo) is an autoimmune disease characterized by the infiltration of exocrine glands by immune cells, especially salivary glands (SG). SG epithelial cells…
Abstract Number: 2198 • ACR Convergence 2023
Which Factors Are Associated with Clinically High Disease Activity in Axial Spondyloarthritis? Results from the International Map of Axial Spondyloarthritis (IMAS)
Marco Garrido-Cumbrera¹, Victoria Navarro-Compán², Fernando Sommerfleck³, Christine Bundy⁴, Souzi Makri⁵, Jose Correa Fernandez⁶, Shashank Murlidhar Akerkar⁷, Jo Davies⁸, Elie Karam⁹, Asif Siddiqui¹⁰ and Denis Poddubnyy¹¹, ¹University of Seville, Sevilla, Spain, ²Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ³Sanatorio Julio Mendez, Buenos Aires, Argentina, ⁴Cardiff University, Cardiff, United Kingdom, ⁵Cyprus League for People with Rheumatism (CYLPER), Nicosia, Cyprus, ⁶Universidad de Sevilla, Health & Territory Research (HTR), Sevilla, Spain, ⁷Mumbai Arthritis Clinic, Mumbai, India, ⁸Axial Spondyloarthritis International Federation (ASIF), London, United Kingdom, ⁹Canadian Spondylitis Association (CSA), Toronto, ON, Canada, ¹⁰Novartis Pharma AG, Basel, Switzerland, ¹¹Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Active axial spondyloarthritis (axSpA) is associated with poorer physical and mental health outcomes. This study aims to assess the prevalence of clinically active disease…
Abstract Number: 2193 • ACR Convergence 2023
Anti-citrullinated Protein Antibodies in Sjögren’s Syndrome Define a Subset of Patients with Lower B Cell Activation Markers and Higher Risk of Lung Involvement
Augusto Silva¹, Filipa Costa², Mariana Silva², Giovanni Fulvio³, Matilde Bandeira², Manuel Silvério-António⁴, Nikita Khmelinskii², Chiara Baldini³ and Vasco Romão², ¹Santa Maria Hospital, Maceira, Portugal, ²Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal, ³University of Pisa, Pisa, Italy, ⁴Hospital Santa Maria, Lisboa, Portugal
Background/Purpose: Extraglandular manifestations may occur in up to 40-50% of patients with SS, including inflammatory arthralgia and chronic polyarthritis (1-3). ACPA are prototypical markers of…
Abstract Number: 2199 • ACR Convergence 2023
Four-year Secukinumab Treatment Outcomes in Axial Spondyloarthritis and Psoriatic Arthritis Patients Treated in Routine Care: Results from the EuroSpA Collaboration
Marion Pons¹, Stylianos Georgiadis¹, Zohra Faizy Ahmadzay², Mikkel Østergaard³, Bente Glintborg¹, Jette Heberg¹, Sara Nysom Christiansen¹, Simon Horskjær Rasmussen¹, Isabel Castrejon⁴, Fernando Alonso⁵, Karin Laas⁶, Sigrid Vorobjov⁷, Nikita Khmelinskii⁸, Jakub Zavada⁹, Adrian Ciurea¹⁰, Michael Nissen¹¹, Brigitte Michelsen¹², Pawel Mielnik¹³, Anne Gitte Loft¹⁴, Ziga Rotar¹⁵, Katja Perdan Pirkmajer¹⁶, Gary Macfarlane¹⁷, Gareth T. Jones¹⁷, Dan Nordstrom¹⁸, Anna-Mari Hokkanen¹⁹, Irene van der Horst-Bruinsma²⁰, Johan Karlsson Wallman²¹, Bjorn Gudbjornsson²², olafur Palsson²³, Merete Hetland¹ and Lykke Ørnbjerg¹, ¹Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, ²Rigshospitalet Glostrup, University of Copenhagen, Glostrup, Denmark, ³Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark, ⁴Hospital Universitario Gregorio Marañón, Madrid, Spain, ⁵Spanish Society of Rheumatology, Madrid, Spain, ⁶Department of Rheumatology, East-Tallinn Central Hospital, Tallinn, Estonia, ⁷National Institute for Health Development, Tallinn, Estonia, ⁸Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal, ⁹Institute of Rheumatology; Charles University, Prague, Czech Republic, ¹⁰University Hospital Zurich, Zürich, Switzerland, ¹¹Geneva University Hospitals, Geneva, Switzerland, ¹²Rigshospitalet Glostrup; Diakonhjemmet Hospital; Sørlandet Hospital, Copenhagen, Denmark, ¹³Section for Rheumatology, Helse Førde, Førde, Norway, ¹⁴Aarhus University, Horsens, Denmark, ¹⁵University Medical Centre Ljubljana, Ljubljana, Slovenia, ¹⁶University Medical Centre Ljubljana; University of Ljubljana, Ljubljana, Slovenia, ¹⁷Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom, ¹⁸Helsinki University Hospital, Helsinki, Finland, ¹⁹Departments of Medicine and Rheumatology, Helsinki University Hospital, Helsinki, Finland, ²⁰Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ²¹Lund University and Skåne University Hospital, Lund, Sweden, ²²Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, ²³Faculty of Medicine, University of Iceland, Reykjavik, Iceland
Background/Purpose: Axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) are part of the spondylarthritis spectrum that can be treated with secukinumab, a fully human IgG1 monoclonal…
Abstract Number: 2187 • ACR Convergence 2023
Association Between Illness Perception, Anxiety and Depression State, Disease Activity and Glucocorticoid Therapy in Patients with Sjӧgren’s Syndrome
Chiara Baldini¹, Elena Elefante², Inmaculada Conception Navarro Garcia², Francesco Ferro³, Gaetano La Rocca⁴, Giovanni Fulvio¹, Silvia Fonzetti⁵, Michele Moretti⁶ and Marta Mosca², ¹University of Pisa, Pisa, Italy, ²Rheumatology Unit, Department of clinical and experimental medicine, University of Pisa, Pisa, Italy, ³Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, ⁴University of Pisa, Rheumatology Unit, Pisa, Italy, ⁵AOUP, Pisa, Italy, ⁶Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
Background/Purpose: Sjӧgren's syndrome (SS) may affect several aspects of patients' daily lives, leading to impairment of quality of life and patient functioning. Aims of this…
Abstract Number: 2150 • ACR Convergence 2023
Novel Biologic IRL201805 Inhibits Osteoclastogenesis in Monocytic Cells from RA Patients
Yuriko Yamamura¹, Valerie Corrigall², Lara Ravanetti³, Jorge De Alba³, Roly Foulkes⁴, Paul Eggleton⁵ and Carl Goodyear⁶, ¹School of Infection & Immunity, University of Glasgow, Glasgow, United Kingdom, ²Revolo Biotherapeutics, Tadworth, United Kingdom, ³Revolo Biotherapeutics, London, United Kingdom, ⁴Revolo Biotherapeutics, Slough, United Kingdom, ⁵Revolo Biotherapeutics, Exeter, United Kingdom, ⁶University of Glasgow, Glasgow, United Kingdom
Background/Purpose: In Rheumatoid arthritis (RA), osteoclasts derived from CD14+ Monocytes are associated with a risk of progressive bone and joint destruction, which fundamentally impacts quality-of-life.…
Abstract Number: 2155 • ACR Convergence 2023
The Impact of Filgotinib on Disease Activity Outcomes with Concomitant Pain Control in the Phase 3 FINCH Studies
Peter C. Taylor¹, Arthur Kavanaugh², Peter Nash³, Janet Pope⁴, Georg Pongratz⁵, Bruno Fautrel⁶, Rieke Alten⁷, Ken Hasegawa⁸, Shangbang Rao⁹, Dick de Vries¹⁰, Pieter-Jan Stiers¹¹, Chris Watson¹² and René Westhovens¹³, ¹Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ³School of Medicine, Griffith University, Brisbane, Australia, ⁴University of Western Ontario, London, ON, Canada, ⁵Faculty of Medicine, Regensburg University, Regensburg, Germany, Regensburg, Germany, ⁶Sorbonne Université APHP, Paris, France, ⁷Department of Internal Medicine and Rheumatology, Schlosspark Klinik, University Medicine Berlin, Berlin, Germany, ⁸Global Medical Affairs Research, Gilead Sciences, Inc., Foster City, CA, ⁹Biostatistics, Gilead Sciences, Inc., Foster City, CA, ¹⁰Research and Development, Clinical Research, Galapagos BV, Leiden, Netherlands, ¹¹Biostatistics, Galapagos NV, Mechelen, Belgium, ¹²Medical Affairs, Galapagos Biotech Ltd., Cambridge, United Kingdom, ¹³Department of Rheumatology, KU Leuven, Skeletal Biology and Engineering Research Center, Leuven, Belgium
Background/Purpose: Patients (pts) with rheumatoid arthritis (RA) often experience substantial pain despite treatment, and consider pain control an important treatment outcome. This post hoc analysis…
Abstract Number: 2174 • ACR Convergence 2023
JAK Inhibitors in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 73 Patients, 55 of Baricitinib
Ana Serrano-Combarro¹, Belén Atienza-Mateo², Jesus Alejandro Valero-Jaimes³, Marta Pastor-Mena⁴, Rafael Benito Melero-Gonzalez⁵, David Castro-Corredor⁶, Maria Martin-Lopez⁷, Santos Castañeda⁸, Jesus Loarce-Martos⁹, Natalia Mena Vazquez¹⁰, Carmen carrasco-Cubero¹¹, Carolina Diez-Morrondo¹², andrea Garcia-Valle¹³, Gema Bonilla¹⁴, Juan Maria Blanco-Madrigal¹⁵, Natividad del Val del Amo¹⁶, Nuria Vegas Revenga¹⁷, Lorena Perez-Albadalejo¹⁸, Rafaela Ortega Castro¹⁹, Deseada Palma-Sanchez²⁰, Ana Maria fernandez-Ortiz²¹, Patricia Lopez-Viejo²², Maria Lopez-Lasanta²³, Marta Garijo Bufort²⁴, Ivette Casafont-Sole²⁵, Olga Maiz-Alonso²⁶, Juan Moreno-Morales²⁷, Ana Urruticoechea²⁸, Carolina Perez-Garcia²⁹, Jose Rosas³⁰, Virginia Ruiz-Esquide³¹, Delia Fernández-Lozano³², Ignacio Brana Abascal³³, Evelin Cecilia Cervantes-Perez³⁴, Julia Fernandez-Melon³⁵, Cristina Fernandez³⁶, Bryan Josue Flores Robles³⁷, Diego Ferrer³⁸ and Ricardo Blanco³⁹, ¹Hospital Universitario Marques de Valdecilla, IDIVAL, Santander, Spain, ²Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Hospital Bidasoa, Irún, Spain, ⁴Hospital de Jerez de la Frontera, Cádiz, Spain, ⁵CHU Vigo, O Carballino, Spain, ⁶General University Hospital of Ciudad Real, Santa Cruz de Mudela (Ciudad Real), Spain, ⁷Hospital 12 de Octubre, Madrid, Spain, ⁸Hospital Universitario de la Princesa, Madrid, Spain, ⁹Ramón y Cajal University Hospital, Madrid, Spain, ¹⁰IBIMA, Málaga, Spain, ¹¹Department of Rheumatology, Hospital Universitario de Badajoz, Badajoz, Spain, ¹²Division of Rheumatology, Hospital de León, León, Spain, ¹³Division of Rheumatology, Complejo Asistencial Universitario de Palencia, Palencia, Spain, ¹⁴Department of Rheumatology, Hospital Clínico Universitario La Paz, Madrid, Spain, ¹⁵Division of Rheumatology, H. Universitario de Basurto, Bilbao, Spain, ¹⁶Complejo Hospitalario de Navarra, Pamplona, Spain, ¹⁷Hospital Galdakao- Usansolo, Galdakao, Spain, ¹⁸Division of Rheumatology, Hospital Universitario de Jaén, Jaén, Spain, ¹⁹Hospital Reina Sofía, Cordoba, Spain, ²⁰Hospital Rafael Mendez, Lorca, Spain, ²¹CHU Badajoz, Badajoz, Spain, ²²Division of Rheumatology, Hospital Severo Ochoa, Leganéz, Spain, ²³Hospital Universitari Vall d'Hebron, Rheumatology, Barcelona, Spain, ²⁴H. de Sagunto, Valencia, Italy, ²⁵Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²⁶University Hospital Donostia, San Sebastian, Spain, ²⁷Hospital Universitario Santa Lucia Cartagena, Cartagena, Spain, ²⁸Hospital Can Misses, Ibiza, Spain, ²⁹Hospital del Mar, Barcelona, Spain, ³⁰Hospital Marina Baixa, Alicante, Spain, ³¹Hospital Clinic, Rheumatology, Barcelona, Spain, ³²Hospital de Mérida, Merida, Spain, ³³Division of Rheumatology, Hospital Universitario Central de Asturias, Oviedo, Spain, ³⁴Complexo Hospitalario Universitario de Pontevedra, Pontevedra, Spain, ³⁵Division of Rheumatology, Hospital Universitario Son Espases, Palma de Mallorca, Spain, ³⁶Hospital Universitario San Juan de Alicante, Alicante, Spain, ³⁷Hospital Universitario San Pedro, Logroño, Spain, ³⁸Division of Pneumology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³⁹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Abatacept and Rituximab are the recommended drugs. JAK inhibitors (JAKi) have…
Abstract Number: 2165 • ACR Convergence 2023
Efficacy of Abatacept in Rheumatoid Arthritis- associated Usual Interstitial Pneumonia. National Multicenter Study of 233 Patients During a Long-Term Follow Up
Belén Atienza-Mateo¹, Ana Serrano-Combarro², Natividad del Val del Amo³, Ivette Casafont-Sole⁴, Rafael Benito Melero-Gonzalez⁵, Isabel Serrano-García⁶, Santos Castañeda⁷, Jerusalem Calvo⁸, Natalia Mena Vazquez⁹, Nuria Vegas Revenga¹⁰, Lucía Domínguez-Casas¹¹, Maria Camila Osorio Sanjuan¹², Carolina Díez Morrondo¹³, Lorena Perez-Albadalejo¹⁴, Ruben Lopez-Sanchez¹⁵, Maria Guadalupe Mazano Canabal¹⁶, Anahy Maria Brandy-Garcia¹⁷, Patricia Lopez-Viejo¹⁸, Gema Bonilla¹⁹, Olga Maiz-Alonso²⁰, Carmen carrasco-Cubero²¹, Marta Garijo Bufort²², Mireia Moreno²³, Ana Urruticoechea²⁴, Sergio Ordonez-Palau²⁵, Carmen Gonzalez-Montagut Gomez²⁶, andrea Garcia-Valle²⁷, Juan Ramon De Dios²⁸, Fernando Lozano²⁹, Tomás Vazquez-Rodriguez³⁰, Patricia Carreira²⁹, Juan Maria Blanco-Madrigal³¹, SARA MARIA ROJAS HERRERA³², Ignacio Brana Abascal³³, Jesus Loarce-Martos³⁴, Emilio Giner-Serret³⁵, Juan Camilo Sarmiento-Monroy³⁶, Clara ventin-Rodriguez³⁷, Marina Rodriguez-lopez³⁸, Pablo Andujar-Brazal³⁹, Julia Fernandez-Melon⁴⁰, Lilian Maria Lopez⁴¹, carlos Fernandez-Diaz⁴², Javier Loricera⁴³, Ivan Ferraz Amaro⁴⁴, Diego Ferrer⁴⁵, Ricardo Blanco⁴⁶ and On behalf of the Collaborative Group Members⁴⁷, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain, ³Complejo Hospitalario de Navarra, Pamplona, Spain, ⁴Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁵CHU Vigo, O Carballino, Spain, ⁶Division of Rheumatology, H. Puerta del Mar, Cádiz, Spain, ⁷Hospital Universitario de la Princesa, Madrid, Spain, ⁸Reina Sofia University Hospital, Córdoba, Spain, ⁹IBIMA, Málaga, Spain, ¹⁰Hospital Galdakao- Usansolo, Galdakao, Spain, ¹¹Division of Rheumatology, Hospital San Agustín, Avilés, Spain, ¹²Division of Rheumatology, H.U. Lozano Blesa, Zaragoza, Spain, ¹³Division of Rheumatology, Hospital de León, León, Spain, ¹⁴Division of Rheumatology, Hospital Universitario de Jaén, Jaén, Spain, ¹⁵Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain, ¹⁶Complejo Asistencial de Zamora, Zamora, Spain, ¹⁷Hospital Germans Trias i Pujol, Badalona, Spain, ¹⁸Division of Rheumatology, Hospital Severo Ochoa, Leganéz, Spain, ¹⁹Department of Rheumatology, Hospital Clínico Universitario La Paz, Madrid, Spain, ²⁰University Hospital Donostia, San Sebastian, Spain, ²¹Department of Rheumatology, Hospital Universitario de Badajoz, Badajoz, Spain, ²²H. de Sagunto, Valencia, Italy, ²³Parc Tauli Hospital Universitari, I3PT(UAB), Barcelona, Spain, ²⁴Hospital Can Misses, Ibiza, Spain, ²⁵H. Arnau de Vilanova, Lleida, Spain, ²⁶H. Clínico Universitario de Valladolid, Valladolid, Spain, ²⁷Division of Rheumatology, Complejo Asistencial Universitario de Palencia, Palencia, Spain, ²⁸Hospital Universitario Araba, Vitoria, Spain, ²⁹Hospital Universitario 12 de Octubre, Madrid, Spain, ³⁰Rheumatology, Complejo Hospitalario Universitario de Ferrol, A Coruña, Spain, ³¹Division of Rheumatology, H. Universitario de Basurto, Bilbao, Spain, ³²Division of Rheumatology, Hospital de Mérida, Mérida, Spain, ³³Division of Rheumatology, Hospital Universitario Central de Asturias, Oviedo, Spain, ³⁴Ramón y Cajal University Hospital, Madrid, Spain, ³⁵Hospital Royo Villanova, Teruel, Spain, ³⁶Hospital Clínic, Barcelona, Spain, ³⁷Division of Rheumatology, Hospital Universitario de A Coruña, A Coruña, Spain, ³⁸Division of Rheumatology, Hospital Clínico Universitario de Santiago, La Coruna, Spain, ³⁹Division of Rheumatology, Hospital Universitario Doctor Peset, Valencia, Spain, ⁴⁰Division of Rheumatology, Hospital Universitario Son Espases, Palma de Mallorca, Spain, ⁴¹Division of Rheumatology, Hospital Universitario Son Llàtzer, Mallorca, Spain, ⁴²Division of Rheumatology, Hospital Universitario Reina Sofía, Murcia, Spain, ⁴³Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴⁴Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁴⁵Division of Pneumology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴⁶Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴⁷Spanish Collaborative Group of Interstitial Lung Disease Associated with Rheumatoid Arthritis, Spain, Spain
Background/Purpose: Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Usual interstitial pneumonia (UIP) is the most frequent, and severe ILD…
Abstract Number: 2178 • ACR Convergence 2023
Increased Risk of Dementia in Patients with Primary Sjogren’s Syndrome: A Nationwide Population-based Cohort Study
Kyung-Ann Lee¹, Hyeji Jeon¹, Hyun-Sook Kim¹ and Gi Hyeon Seo², ¹Soonchunhyang University Seoul Hospital, Seoul, South Korea, ²Health Insurance Review and Assessment Service, Wonju, South Korea
Background/Purpose: Autoimmunity and systemic inflammation may play a role in early-stage dementia. Few studies have investigated whether primary Sjogren's syndrome (pSS) increases the risk of…
Abstract Number: 2185 • ACR Convergence 2023
35 Years Follow-up of Primary Sjögren’s Disease: A Single Center Study
Lorena Montano-Tapia¹, Resit Yildrim², Ana Mafalda Abrantes³ and David Isenberg⁴, ¹Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain, ²Eskişehir Osmangazi University I, Eskişehir, Turkey, ³Centro Hospitalar Universitario Lisboa Norte, Lisbon, Portugal, ⁴University College London, London, United Kingdom
Background/Purpose: Primary Sjögren’s syndrome (pSS) is an autoimmune rheumatic disease characterized by lymphocytic infiltration of exocrine glands. Its clinical manifestations are heterogeneous. Currently, the evidence…
Abstract Number: 2206 • ACR Convergence 2023
Increased Frequency of Activated MAIT Cells Expressing the Gut Homing Receptor CCR9 in Patients with Radiographic Axial Spondyloarthritis
Eric Toussirot¹, Caroline Laheurte², Eléonore Gravelin², Charline Vauchy³, Marc Puyraveau³ and Philippe Saas⁴, ¹University Hospital of Besancon, Besançon, France, ²INSERM UMR1098, plateforme de biomonitoring, EFS Bourgogne-Franche-Comté, Besançon, France, ³INSERM CIC-1431, Besançon, France, ⁴INSERM UMR1098, EFS Bourgogne-Franche-Comté, Besançon, France
Background/Purpose: MAIT (mucosal associated invariant T) cells are involved in mucosa defense against bacteria. This cellular subset is characterized by a semi-invariant αβ TCR and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].